|
Orthologous residues
|
|
MeCP2 (human): S423‑p, MeCP2 (mouse): S421‑p, MeCP2 iso2 (mouse): S438‑p, MeCP2 (rat): S421‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'brain, forebrain', 'neuron, cortical'-brain [MeCP2 (mouse), genetic knockin], neuron-'brain, hippocampus'
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
mouse
|
|
Comments:
MeCP2 mutation link to Rett syndrome
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
depolarization
|
|
|
|
increase
|
|
|
okadaic acid
|
depolarization
|
|
|
inhibit treatment-induced increase
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
depolarization
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
chromatin organization, altered, cytoskeletal reorganization
|
|
Comments:
Regulates dendritic remodeling, membrane depolarization; neuronal activation leading to S421 phosphorylation and global chromatin response; S421A mutant mice have behavioral defects in response to novel experience.
|
